VIGILANTNCT07177339
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoints: details revised at 1 of 1 entry Show 5 more changesShow less
- Eligibility criteria shortened, about 3 words
- Trial sites expanded: 121 → 293 locations
- Primary completion date: Apr 30, 2029 to Apr 2, 2029
- Study completion date: Jun 8, 2029 to Jun 4, 2029
- Secondary endpoints: details revised at 3 of 3 entries
- Minor Trial sites expanded: 6 → 121 locations
- Primary completion moved earlier from Nov 2, 2029 to Apr 30, 2029
- Study completion moved earlier from Dec 14, 2029 to Jun 8, 2029
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Primary completion date: Oct 19, 2029 to Nov 2, 2029
- Minor Primary completion date: Nov 16, 2029 to Oct 19, 2029
- Study completion date: Jan 11, 2030 to Dec 14, 2029
- Start date: Nov 17, 2025 to Oct 20, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants with Chronic Obstructive Pulmonary Disorder (COPD) with Type 2 inflammation will receive Depemokimab in combination with existing Standard of Care (SoC).
Participants with COPD with Type 2 inflammation will receive matching Placebo in combination with existing SoC.
Drugs: Depemokimab, Placebo
Sites
293 sites in 25 countries
United States 75, China 47, Japan 36, Germany 20, Argentina 14, United Kingdom 12, Spain 11, Bulgaria 9, Israel 8, South Korea 8, France 7, Greece 6, Poland 6, Canada 5, Denmark 4, Belgium 3, Brazil 3, Italy 3, New Zealand 3, Romania 3, Taiwan 3, Australia 2, Hungary 2, Netherlands 2, Chile 1